A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies is an option in select patients after an initial allograft has failed. If the original donor is not available, a different donor may have to be considered. We report our experience of performing a second allogeneic HSCT using a different donor in patients with relapsed leukemia and lymphoma. In a 5-year period, six patients underwent a second allograft with myeloablative conditioning using a different donor. Four of these were retransplanted using a matched-unrelated donor. Four of the patients (67%) remain progression-free at a median follow-up of 32 months (range 3-72). There were no cases of transplantrelated mortality. We conclude that a second allogeneic HSCT using a different donor is a viable option for selected patients relapsing after an allograft if the original donor is not available.
Summary:
A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies is an option in select patients after an initial allograft has failed. If the original donor is not available, a different donor may have to be considered. We report our experience of performing a second allogeneic HSCT using a different donor in patients with relapsed leukemia and lymphoma. In a 5-year period, six patients underwent a second allograft with myeloablative conditioning using a different donor. Four of these were retransplanted using a matched-unrelated donor. Four of the patients (67%) remain progression-free at a median follow-up of 32 months (range 3-72). There were no cases of transplantrelated mortality. We conclude that a second allogeneic HSCT using a different donor is a viable option for selected patients relapsing after an allograft if the original donor is not available. is potentially curative therapy for a variety of hematologic malignancies. However, acute leukemia patients with unfavorable cytogenetic features as well as those with blast phase CML are at high risk of relapse even after an allograft. 1 The options for treatment in such circumstances include donor lymphocyte infusions (DLI) with or without chemotherapy or a second allograft. The effectiveness of a second allograft depends on the underlying malignancy and time to relapse after the first HSCT. 2, 3 Recent registry reviews of second HSCT for relapsed leukemia show disease-free survival rates of 25-30%. 4, 5 Most patients in published series have been re-transplanted using their original donor. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] On occasion, the original donor may not be available for, or may refuse a second collection of cells, so the use of a different donor may need to be considered in patients who have disease that is controllable to the point where a second donor can be identified and stem cells procured. However, it is unclear whether the use of a different donor increases the already considerable risk of a second HSCT in terms of treatment-related mortality (TRM), rates of engraftment and graft-versus-host disease (GVHD). We have examined our experience using a different donor for second HSCT, looking at both feasibility and utility of the procedure.
Patients and methods

Patients
After obtaining permission from the Loyola University Medical Center's institutional review board, a retrospective medical chart and bone marrow transplant database review was performed. Patients receiving donor bone marrow, blood stem cells or DLI for post allograft relapsed hematologic malignancy between February 1999 and April 2004 were identified. Of these, the patients who underwent a second allogeneic HSCT using a different donor after conventional conditioning were included in the study.
Eligibility criteria and transplant procedure
Patients undergoing second HSCT were required to have adequate renal, hepatic and cardio-pulmonary function as well as functional status. Donor selection required matching at the serologic level for HLA-A, B, C and at the molecular level for HLA-DRB1. Second HSCT was performed using a different donor if the original donor refused or was unavailable, and in one instance, because the patient had rejected the original graft. Preparative regimens for second HSCT were selected based on prior therapies and the clinical condition of the patient. The source of hematopoietic stem cells was either G-CSF mobilized peripheral blood or un-manipulated bone marrow. GVHD prophylaxis consisting of methotrexate plus either tacrolimus or cyclosporin was used in all patients.
Outcomes evaluated and statistical analysis
Neutrophil engraftment was defined as the number of days after HSCT to reach a sustained absolute neutrophil count (ANC) of 0.5 Â 10 9 /l. Platelet engraftment was defined as the time to reach a sustained platelet count of 20 Â 10 9 /l without the use of transfusions. Donor-recipient chimerism was determined by PCR analysis on whole blood for short tandem repeat (STR) sequences (City of Hope National Medical Center, Duarte, CA, USA) and results were expressed as percent donor-derived DNA. Acute and chronic GVHD were graded according to published standards. 17, 18 Overall survival (OS) was defined as the time from second HSCT to death or date of last follow-up. Event-free survival (EFS) was defined as the time from second HSCT until either clinical or pathological evidence of disease progression, graft rejection, death, or last followup. Establishment of complete remission (CR) status for leukemia patients required a normo-cellular bone marrow with no morphologic evidence of leukemia and normalization of peripheral blood counts. TRM was defined as death attributable to interstitial pneumonitis, veno-occlusive disease or infection related to the conditioning regimen or to acute and chronic GVHD.
Results
Patient characteristics
During the 62-month study period 278 patients received an allogeneic HSCT at our institution. Of these, 21 patients underwent a second HSCT with myeloablative conditioning for treatment of post-allograft relapse of hematologic malignancies. Six of these patients were transplanted using a different donor. Patient characteristics are detailed in Tables 1 and 2 . Median age at second transplant was 45.5 years (range 18-51 years); median ECOG performance status was 0 (range 0-2). Most patients were in an advanced stage of disease at time of second HSCT, and most were extensively pretreated (Tables 1 and 2 ). One patient had Richter's transformation of NHL and had rejected a nonmyeloablative allogeneic HSCT from his HLA-identical brother. One patient with chemotherapy-related AML/ MDS had a history suggestive of Li-Fraumeni syndrome, with prior osteosarcoma and anaplastic oligoastrocytoma in the patient and his sister. Both AML patients had complex karyotypic abnormalities as well, including monosomy 7 and t(11:19) involving the MLL locus.
Second HSCT procedures
Standard myeloablative regimens were administered as conditioning for the second transplant ( Table 2) . Of the six patients, four were retransplanted using an URD, one matched-related donor (MRD) and one 5/6 MRD (mismatch being at the HLA-A locus). Five patients received unmanipulated bone marrow grafts and one patient received G-CSF mobilized peripheral blood stem cells from a MRD. Median mononuclear cell dose was 2.66 Â 10 8 MNC/kg in this group (range 1.9-9.4). Four patients received gender-matched BMT for both transplants. Three patients had major ABO incompatibility with the second donor and one had a minor ABO incompatibility. 
Survival and engraftment
Five of six patients (84%) achieved CR following second HSCT ( Table 2) . Of these patients, as of April 2004 four remain alive in remission at a median follow-up of 32 months (range 3-72 months). Median OS and EFS are 23 months (range 3-72 months) and 22 months (range 1-72 months). Two patients have succumbed to disease progression (Table 2) . Five patients had full hematologic reconstitution; one patient failed to engraft platelets at a follow-up of 3 months. Neutrophil and platelet engraftment occurred at a median time of 15 (range 12-22 days) and 23 days (range 9-54 days), respectively. The four patients who are alive have 100% donor-derived DNA in blood at 2, 4, 12, and 24 months, respectively, following transplant. A fifth patient with AML was 100% donor chimeric until relapse at 22 months. No evidence of the prior graft was seen in any patient after the second HSCT. The patient with MDS/secondary AML who received BEAM conditioning and BMT from a different URD lost his second allograft at day þ 30 developing disease progression, after achieving transient mixed donor-recipient chimerism.
Toxicities and complications
The incidence of regimen-related toxicities and GVHD was low (Table 2) . Steroid responsive acute GVHD developed in two patients; one receiving mismatched-related donor (grade III -skin and gastrointestinal tract), and the other URD (grade II -skin and liver) bone marrow transplant. The latter patient also developed hypoxia with pulmonary infiltrates and a sterile pericardial effusion coincident with engraftment and subsequently went on to develop interstitial pneumonitis complicated by pneumomediastinum. Another URD BMT patient developed a sterile pericardial effusion at the time of engraftment as well. Limited chronic GVHD occurred in one patient and extensive chronic GVHD in three patients, involving the liver, skin, and mucous membranes. The two deaths that did occur were due to relapsed AML. There were no instances of TRM.
Discussion
We report here outcomes in a small cohort of patients who underwent a second allogeneic stem cell transplant for relapsed hematologic malignancies using a different donor. Despite receiving conventional myeloablative conditioning and standard GVHD prophylaxis for the second transplant, most patients tolerated this therapy well and achieved hematopoietic engraftment. At a median followup of nearly 3 years, 67% of the patients are alive and in remission. Achievement of prolonged disease remissions in these refractory patients suggests a graft-versus-tumor effect attributable to the use of a different donor. These observations serve to validate the plausibility of using a different donor for retransplanting patients with relapsed hematologic malignancies.
Although observed in a small patient cohort, these outcomes compare favorably with what has been reported in the literature for second allografts in general; this may reflect the more indolent disease biology in these patients as demonstrated by their relatively long remissions after the first transplant. Other studies have identified various factors to be associated with improved outcome after a second allograft, such as longer interval to relapse following first HSCT, [4] [5] [6] 10, 13, 15 complete remission status at second transplant, 4, 6, 10 younger age, 5,9 use of a female donor 5 and presence of acute or chronic GVHD following the second transplant. [4] [5] [6] 13 European registry studies have shown 5 year OS rates of 26-32% and TRM rates of 45-46% following a second HSCT. 4, 5 Several studies have reported the use of a different donor for the second transplant. The Socie´te´Franc¸aise de Greffe de Moelle have published their experience with second HSCT in relapsed leukemia, encompassing 150 patients, with 17% being transplanted with a different donor. 5 No significant difference in outcome was seen when comparing these patients with those transplanted using the same donor with similar 2-year survival (41 vs 39%; P ¼ 0.7) and TRM (41 vs 49%; P ¼ 0.8). Mrsic et al 10 reported 11/114 leukemia patients undergoing a second allogeneic BMT with a different related donor, again with a similar 2-year survival (14 vs 21%; P ¼ NS) when compared to those transplanted Post-allograft relapse is due to incomplete cytoreduction by the conditioning regimen and a failure of the graftversus-malignancy effect. Given that the second preparative regimen in our series was in general no more intensive than that used for the first HSCT, the relatively long remissions observed in these very poor-risk patients point to an immune-mediated antitumor effect exerted by the second donor's immune effectors. This may be because the second donors have minor histoincompatibilities or killer inhibitory receptor (KIR) incompatibilities with the recipient, which makes them more apt to mount such an antitumor response, where the original donor had failed. 19, 20 Indeed, only 25% of matched related donor-recipient pairs who are HLA identical are also KIR identical, with KIR identity almost never being seen in URD-HSCT. 19 It may be in part due to such incompatibilities that in our cohort, all the patients who have become long-term survivors following a second transplant did develop chronic GVHD. However, encouragingly, it does not appear that the risk of lifethreatening acute GVHD is higher than when using the same donor in similar circumstances. Graft rejection however remains a risk, mandating the use of doseintensive and adequately immunosuppressive conditioning, which will limit the applicability of this modality to otherwise fit individuals only.
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In conclusion, our data suggest that a second fully ablative allogeneic transplant using a different donor for high risk, refractory hematologic malignancies is feasible for selected patients when the original donor is not available. Although encouraging, these findings reflect observations made on a small cohort of patients and therefore need confirmation in larger studies. Given the small number of patients in our study the question of comparability between using the same vs a different donor for a second HSCT for relapsed hematologic malignancy needs more scrutiny and to this end an NMDP-IBMTR study is being proposed.
